Related Experiment Video
Updated: May 13, 2026
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Targeting miR-21 for the therapy of pancreatic cancer
Flavie Sicard1, Marion Gayral, Hubert Lulka
1INSERM U1037, Cancer Research Center of Toulouse, Toulouse, France.
Abstract:
Despite tremendous efforts worldwide from clinicians and cancer scientists, pancreatic ductal adenocarcinoma (PDA) remains a deadly disease for which no cure is available. Recently, microRNAs (miRNAs) have emerged as key actors in carcinogenesis and we demonstrated that microRNA-21 (miR-21), oncomiR is expressed early during PDA. In the present study, we asked whether targeting miR-21 in human PDA-derived cell lines using lentiviral vectors (LVs) may impede tumor growth. We demonstrated that LVs-transduced human PDA efficiently downregulated miR-21 expression, both in vitro and in vivo. Consequently, cell proliferation was strongly inhibited and PDA-derived cell lines died by apoptosis through the mitochondrial pathway. In vivo, miR-21 depletion stopped the progression of a very aggressive model of PDA, to induce cell death by apoptosis; furthermore, combining miR-21 targeting and chemotherapeutic treatment provoked tumor regression. We demonstrate herein for the first time that targeting oncogenic miRNA strongly inhibit pancreatic cancer tumor growth both in vitro and in vivo. Because miR-21 is overexpressed in most human tumors; therapeutic delivery of miR-21 antagonists may still be beneficial for a large number of cancers for which no cure is available.
Insights
Targeting microRNA-21 (miR-21) in pancreatic ductal adenocarcinoma (PDA) using lentiviral vectors significantly inhibits tumor growth and induces apoptosis. This approach shows promise for treating pancreatic cancer and potentially other cancers overexpressing miR-21.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer with limited treatment options.
- MicroRNAs (miRNAs), specifically microRNA-21 (miR-21), are implicated in PDA development.
- miR-21 is an oncomiR, promoting cancer progression.
Purpose of the Study:
- To investigate the therapeutic potential of targeting miR-21 in human PDA.
- To evaluate the efficacy of lentiviral vectors (LVs) for delivering miR-21 antagonists.
- To assess the impact of miR-21 inhibition on PDA cell proliferation, apoptosis, and tumor growth.
Main Methods:
- Utilized lentiviral vectors (LVs) to transduce human PDA cell lines.
- Assessed miR-21 downregulation in vitro and in vivo.
- Analyzed cell proliferation and apoptosis induction via the mitochondrial pathway.
- Evaluated tumor progression in an aggressive PDA mouse model.
- Investigated the combination of miR-21 targeting with chemotherapy.
Main Results:
- LVs efficiently downregulated miR-21 expression in PDA cells.
- miR-21 inhibition led to significant suppression of cell proliferation and induced apoptosis.
- In vivo, miR-21 depletion halted PDA progression and promoted apoptosis.
- Combination therapy with miR-21 antagonists and chemotherapy resulted in tumor regression.
Conclusions:
- Targeting oncogenic miR-21 effectively inhibits pancreatic cancer growth both in vitro and in vivo.
- miR-21 inhibition represents a promising therapeutic strategy for PDA.
- miR-21 antagonists may offer a broadly applicable treatment for various cancers overexpressing miR-21.
